2026 Q2 -tulosraportti
29 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,98%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 341 | - | - | ||
| 722 | - | - | ||
| 500 | - | - | ||
| 1 000 | - | - | ||
| 5 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sittenNice rise in US 💰📈
·3 t sittenNovo Nordisk sees a fundamental change in the treatment of diabetes, obesity, and cardiovascular diseases. The focus is increasingly on organ protection and the prevention of long-term complications – not just on lowering blood sugar or reducing body weight. According to Henrik Jarlov, Vice President for Global Medical Affairs, Diabetes and Cardiovascular at Novo Nordisk, this development means that diabetes treatment, cardiology, nephrology, and obesity treatment are increasingly integrated around the individual patient. The goal is to choose treatments that can simultaneously reduce the risk of damage to the heart and kidneys, among other organs. Semaglutide is a central example of this development. Studies such as SUSTAIN 6, SELECT, and SOUL have shown cardiovascular benefits in various patient groups and with both injectable and oral formulations. Jarlov emphasizes, however, that the cardiovascular effects cannot automatically be considered a common effect for all GLP-1 treatments – each drug should be evaluated based on its own clinical documentation. An important point is that the cardiovascular benefits of semaglutide cannot necessarily be explained solely by weight loss. Data suggest that other mechanisms, including effects on blood pressure, inflammation, metabolic risk factors, and blood vessels, may also play a role. The future treatment of obesity is therefore also expected to become more individualized. For some patients, the greatest possible weight loss will be the most important goal, while others may benefit more from treatment focusing on, for example, organ protection, preservation of physical function, tolerability, or ease of use. This can be particularly relevant for elderly and frail patients, where a significant loss of muscle mass can be a concern. Novo Nordisk is simultaneously investigating new possibilities to reduce the so-called residual cardiovascular risk, partly through research into inflammation. Although the Phase 3 study ZEUS with ziltivekimab did not show a reduction in major cardiovascular events, the company continues other research programs in IL-6 inhibition. One of the biggest challenges in the coming years, however, will be to ensure that existing clinical evidence is actually translated into practice. Many patients who could potentially benefit from modern cardiometabolic treatments still do not receive them. The main message is therefore that the treatment goal is shifting: From primarily controlling blood sugar and weight to increasingly preventing damage to the heart, kidneys, and other organs – preferably before disease damage occurs.
3 t sittenHU - HA Tsingis Khan, kaikkien Novolaisten kauhea alistaja HU -HA Tsingis Khan, kaikkien pillerien karmea dominoija Hu! h! huhahhuhhhuhahuhhahuhhha!
Uncle Tesla, now you just take it veeery easy. You've got Novo-GAKitis. Now sit down calmly, and we'll send a car with two men in white coats over to you - and then you'll sleep so well tonight.
·3 t sitten · MuokattuMany accusations of conspiracies and shorts driving the stock. The simple truth was sector rotation, which via algorithms sells off health care stocks across the board, to buy into tech. Yesterday the rotation was opposite into health care. You can look at any stock in the sector like Merck, Pfizer, Abbvie, eli lilly. They all made the same price reaction down at market opening, to steadily rise back towards the evening. I have fortunately muted most who use column space on conspiracies and comment on a price that goes up and down, without other beneficial information. But the list only gets longer these days on the forum.
You are right. It seems that the big players do this sector rotation often. It's indeed a brilliant way to make money, if one can ride on its coattails.
5 t sitten😂😂😂
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 38 000 | 38 000 | 0 | 38 000 |
| Anonyymi | 4 738 219 | 4 738 219 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 38 000 | 38 000 | 0 | 38 000 |
| Anonyymi | 4 738 219 | 4 738 219 | 0 | 0 |
2026 Q2 -tulosraportti
29 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,98%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenNice rise in US 💰📈
- ·3 t sittenNovo Nordisk sees a fundamental change in the treatment of diabetes, obesity, and cardiovascular diseases. The focus is increasingly on organ protection and the prevention of long-term complications – not just on lowering blood sugar or reducing body weight. According to Henrik Jarlov, Vice President for Global Medical Affairs, Diabetes and Cardiovascular at Novo Nordisk, this development means that diabetes treatment, cardiology, nephrology, and obesity treatment are increasingly integrated around the individual patient. The goal is to choose treatments that can simultaneously reduce the risk of damage to the heart and kidneys, among other organs. Semaglutide is a central example of this development. Studies such as SUSTAIN 6, SELECT, and SOUL have shown cardiovascular benefits in various patient groups and with both injectable and oral formulations. Jarlov emphasizes, however, that the cardiovascular effects cannot automatically be considered a common effect for all GLP-1 treatments – each drug should be evaluated based on its own clinical documentation. An important point is that the cardiovascular benefits of semaglutide cannot necessarily be explained solely by weight loss. Data suggest that other mechanisms, including effects on blood pressure, inflammation, metabolic risk factors, and blood vessels, may also play a role. The future treatment of obesity is therefore also expected to become more individualized. For some patients, the greatest possible weight loss will be the most important goal, while others may benefit more from treatment focusing on, for example, organ protection, preservation of physical function, tolerability, or ease of use. This can be particularly relevant for elderly and frail patients, where a significant loss of muscle mass can be a concern. Novo Nordisk is simultaneously investigating new possibilities to reduce the so-called residual cardiovascular risk, partly through research into inflammation. Although the Phase 3 study ZEUS with ziltivekimab did not show a reduction in major cardiovascular events, the company continues other research programs in IL-6 inhibition. One of the biggest challenges in the coming years, however, will be to ensure that existing clinical evidence is actually translated into practice. Many patients who could potentially benefit from modern cardiometabolic treatments still do not receive them. The main message is therefore that the treatment goal is shifting: From primarily controlling blood sugar and weight to increasingly preventing damage to the heart, kidneys, and other organs – preferably before disease damage occurs.
- 3 t sittenHU - HA Tsingis Khan, kaikkien Novolaisten kauhea alistaja HU -HA Tsingis Khan, kaikkien pillerien karmea dominoija Hu! h! huhahhuhhhuhahuhhahuhhha!Uncle Tesla, now you just take it veeery easy. You've got Novo-GAKitis. Now sit down calmly, and we'll send a car with two men in white coats over to you - and then you'll sleep so well tonight.
- ·3 t sitten · MuokattuMany accusations of conspiracies and shorts driving the stock. The simple truth was sector rotation, which via algorithms sells off health care stocks across the board, to buy into tech. Yesterday the rotation was opposite into health care. You can look at any stock in the sector like Merck, Pfizer, Abbvie, eli lilly. They all made the same price reaction down at market opening, to steadily rise back towards the evening. I have fortunately muted most who use column space on conspiracies and comment on a price that goes up and down, without other beneficial information. But the list only gets longer these days on the forum.You are right. It seems that the big players do this sector rotation often. It's indeed a brilliant way to make money, if one can ride on its coattails.
- 5 t sitten😂😂😂
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 341 | - | - | ||
| 722 | - | - | ||
| 500 | - | - | ||
| 1 000 | - | - | ||
| 5 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 38 000 | 38 000 | 0 | 38 000 |
| Anonyymi | 4 738 219 | 4 738 219 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 38 000 | 38 000 | 0 | 38 000 |
| Anonyymi | 4 738 219 | 4 738 219 | 0 | 0 |
2026 Q2 -tulosraportti
29 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
3,75 DKK/osake
Viimeisin osinko
3,98%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenNice rise in US 💰📈
- ·3 t sittenNovo Nordisk sees a fundamental change in the treatment of diabetes, obesity, and cardiovascular diseases. The focus is increasingly on organ protection and the prevention of long-term complications – not just on lowering blood sugar or reducing body weight. According to Henrik Jarlov, Vice President for Global Medical Affairs, Diabetes and Cardiovascular at Novo Nordisk, this development means that diabetes treatment, cardiology, nephrology, and obesity treatment are increasingly integrated around the individual patient. The goal is to choose treatments that can simultaneously reduce the risk of damage to the heart and kidneys, among other organs. Semaglutide is a central example of this development. Studies such as SUSTAIN 6, SELECT, and SOUL have shown cardiovascular benefits in various patient groups and with both injectable and oral formulations. Jarlov emphasizes, however, that the cardiovascular effects cannot automatically be considered a common effect for all GLP-1 treatments – each drug should be evaluated based on its own clinical documentation. An important point is that the cardiovascular benefits of semaglutide cannot necessarily be explained solely by weight loss. Data suggest that other mechanisms, including effects on blood pressure, inflammation, metabolic risk factors, and blood vessels, may also play a role. The future treatment of obesity is therefore also expected to become more individualized. For some patients, the greatest possible weight loss will be the most important goal, while others may benefit more from treatment focusing on, for example, organ protection, preservation of physical function, tolerability, or ease of use. This can be particularly relevant for elderly and frail patients, where a significant loss of muscle mass can be a concern. Novo Nordisk is simultaneously investigating new possibilities to reduce the so-called residual cardiovascular risk, partly through research into inflammation. Although the Phase 3 study ZEUS with ziltivekimab did not show a reduction in major cardiovascular events, the company continues other research programs in IL-6 inhibition. One of the biggest challenges in the coming years, however, will be to ensure that existing clinical evidence is actually translated into practice. Many patients who could potentially benefit from modern cardiometabolic treatments still do not receive them. The main message is therefore that the treatment goal is shifting: From primarily controlling blood sugar and weight to increasingly preventing damage to the heart, kidneys, and other organs – preferably before disease damage occurs.
- 3 t sittenHU - HA Tsingis Khan, kaikkien Novolaisten kauhea alistaja HU -HA Tsingis Khan, kaikkien pillerien karmea dominoija Hu! h! huhahhuhhhuhahuhhahuhhha!Uncle Tesla, now you just take it veeery easy. You've got Novo-GAKitis. Now sit down calmly, and we'll send a car with two men in white coats over to you - and then you'll sleep so well tonight.
- ·3 t sitten · MuokattuMany accusations of conspiracies and shorts driving the stock. The simple truth was sector rotation, which via algorithms sells off health care stocks across the board, to buy into tech. Yesterday the rotation was opposite into health care. You can look at any stock in the sector like Merck, Pfizer, Abbvie, eli lilly. They all made the same price reaction down at market opening, to steadily rise back towards the evening. I have fortunately muted most who use column space on conspiracies and comment on a price that goes up and down, without other beneficial information. But the list only gets longer these days on the forum.You are right. It seems that the big players do this sector rotation often. It's indeed a brilliant way to make money, if one can ride on its coattails.
- 5 t sitten😂😂😂
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 341 | - | - | ||
| 722 | - | - | ||
| 500 | - | - | ||
| 1 000 | - | - | ||
| 5 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 38 000 | 38 000 | 0 | 38 000 |
| Anonyymi | 4 738 219 | 4 738 219 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 38 000 | 38 000 | 0 | 38 000 |
| Anonyymi | 4 738 219 | 4 738 219 | 0 | 0 |